Hereditary Optic Neuropathy

A one-time injection of Lumevoq demonstrated sustained visual acuity improvements with a favorable safety profile at 5 years in patients with Leber hereditary optic neuropathy, according to a press release from GenSight Biologics.

NR082, a gene therapy drug candidate for the treatment of Leber hereditary optic neuropathy, was granted orphan drug designation by the European Medicines Agency, according to a press release from Neurophth Therapeutics.

Lumevoq demonstrated continued vision improvement in Leber hereditary optic neuropathy 4 years after a single gene therapy injection, according to a press release from GenSight Biologics.

The FDA has granted orphan drug designation to Mitotech for Visomitin, a topical treatment for Leber hereditary optic neuropathy, according to a press release.

A long-term phase 4 trial investigating Raxone for the treatment of Leber’s hereditary optic neuropathy met its primary endpoint, according to a press release from Santhera Pharmaceuticals.

NEPTUNE, N.J. – All retinal ganglion cells are equally damaged in most retinal neuropathies, but a case presented here at the New Jersey Academy of Optometry continuing education event showed that these cells are preserved in Leber’s hereditary optic neuropathy.

A patient at France’s National Eye Hospital of the Quinze-Vingts has been granted temporary authorization for use of Lumevoq, GenSight Biologics’ gene therapy for the treatment of Leber hereditary optic neuropathy, according to a press release.

SAN FRANCISCO — A gene therapy treatment candidate for Leber hereditary optic neuropathy bilaterally improved best corrected visual acuity during a phase 3 trial, according to a speaker here.